Przepiorka, MD, PhD, formerly of the Baylor College of Medicine and now at the
University of Tennessee, Memphis, has become chair of the Food and Drug
Administration’s Oncologic Drugs Advisory Committee (ODAC). She replaces Stacy
Nerenstone, MD, of Hartford Hospital in Connecticut, whose term expired. Dr.
Przepiorka’s research has focused largely on transplantation immunobiol-ogy and
she has a background in cellular and gene therapy. Her term as committee chair
will end on June 30, 2004.
FDA also appointed three new members to 4-year terms on the
advisory panel: Bruce D. Cheson, MD, head of hematology at Georgetown
University’s Lombardi Cancer Center; Silvana Martino, DO, head of the Medical
Oncology-Breast Cancer Section at the John Wayne Cancer Institute-St. Johns
Health Center, Santa Monica, California; and Gregory H. Reaman, MD, executive
director of the Center for Cancer & Blood Disorders at Children’s National
Medical Center, Washington, DC.